Recent developments in Alzheimer's disease therapeuti

BMC Medicine

7, 7

DOI: 10.1186/1741-7015-7-7

Citation Report

#	Article	IF	Citations
1	Development of a High-Throughput Assay for Screening of Î³-Secretase Inhibitor with Endogenous Human, Mouse or Drosophila Î³-Secretase. Molecules, 2009, 14, 3589-3599.	1.7	11
2	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Review of Neurotherapeutics, 2009, 9, 1413-1431.	1.4	120
3	Packages of Care for Dementia in Low- and Middle-Income Countries. PLoS Medicine, 2009, 6, e1000176.	3.9	70
4	Preclinical Properties of ¹⁸F-AV-45: A PET Agent for AÎ² Plaques in the Brain. Journal of Nuclear Medicine, 2009, 50, 1887-1894.	2.8	396
6	Cerebrospinal fluid tau and ptau ₁₈₁ increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease. EMBO Molecular Medicine, 2009, 1, 371-380.	3.3	315
7	Versatile Somatic Gene Transfer for Modeling Neurodegenerative Diseases. Neurotoxicity Research, 2009, 16, 329-342.	1.3	11
8	Commentary on â€œAlzheimer's disease drug development and the problem of the blood-brain barrier.â€• The blood-brain barrier: A physical and conceptual challenge. , 2009, 5, 435-436.		5
9	Neurodegenerative disorders and nanoformulated drug development. Nanomedicine, 2009, 4, 541-555.	1.7	61
10	Neurobiology of cognitive disorders. Current Opinion in Psychiatry, 2009, 22, 546-551.	3.1	24
11	AD Vaccines: Conclusions and Future Directions. CNS and Neurological Disorders - Drug Targets, 2009, 8, 160-166.	0.8	11
12	Genetic and Genomic Aspects of Alzheimer's Disease. Proceedings of Singapore Healthcare, 2010, 19, 334-341.	0.2	0
13	ALZHEIMER DISEASE UPDATE. CONTINUUM Lifelong Learning in Neurology, 2010, 16, 15-30.	0.4	7
14	Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?. Journal of Alzheimer's Disease, 2010, 19, 405-421.	1.2	26
15	Chinese Herbal Medicine: Perspectives on Age-Related Neurodegenerative Diseases. Annals of Traditional Chinese Medicine, 2010, , 143-170.	0.1	0
17	Vaccination as a Therapeutic Approach to Alzheimer's Disease. Mount Sinai Journal of Medicine, 2010, 77, 17-31.	1.9	43
18	A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimerâ€™s disease. Psychopharmacology, 2010, 207, 637-643.	1.5	202
19	Immunotherapeutic approaches for Alzheimerâ€™s disease in transgenic mouse models. Brain Structure and Function, 2010, 214, 201-218.	1.2	36
20	Chronic psychosocial stress triggers cognitive impairment in a novel at-risk model of Alzheimer's disease. Neurobiology of Disease, 2010, 37, 756-763.	2.1	55

#	Article	IF	Citations
21	Alzheimerâ€™s disease biomarker discovery in symptomatic and asymptomatic patients: Experimental approaches and future clinical applications. Experimental Gerontology, 2010, 45, 15-22.	1.2	34
22	Heparin/heparan sulphate-based drugs. Drug Discovery Today, 2010, 15, 1058-1069.	3.2	98
23	Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease. Annals of Neurology, 2010, 68, 446-453.	2.8	128
24	A highly sensitive peptide substrate for detecting two AÎ²-degrading enzymes: Neprilysin and insulin-degrading enzyme. Journal of Neuroscience Methods, 2010, 190, 57-62.	1.3	19
25	Structure-based design and synthesis of novel P2/P3 modified, non-peptidic Î²-secretase (BACE-1) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1924-1927.	1.0	24
26	Discovery of sulfonamideâ€“pyrazole Î³-secretase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2148-2150.	1.0	18
27	Why Alzheimer's Disease Starts with a Memory Impairment: Neurophysiological Insight. Journal of Alzheimer's Disease, 2010, 20, 5-16.	1.2	23
28	Peptide mass-assisted antibody cloning strategy for accurate characterization of potential therapeutic monoclonal antibodies against neurodegenerative diseases. Protein Engineering, Design and Selection, 2010, 23, 203-210.	1.0	4
29	Quantitative structural MRI for early detection of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2010, 10, 1675-1688.	1.4	57
30	Bepridil and Amiodarone Simultaneously Target the Alzheimer's Disease Â- and Â-Secretase via Distinct Mechanisms. Journal of Neuroscience, 2010, 30, 8974-8983.	1.7	51
31	Systemic Immune Responses in Alzheimer's Disease: In Vitro Mononuclear Cell Activation and Cytokine Production. Journal of Alzheimer's Disease, 2010, 21, 181-192.	1.2	81
32	Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives. Journal of Medicinal Chemistry, 2010, 53, 5129-5143.	2.9	69
33	Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 847-859.	1.8	71
34	Protective effect of systemic l-kynurenine and probenecid administration on behavioural and morphological alterations induced by toxic soluble amyloid beta (25â€“35) in rat hippocampus. Behavioural Brain Research, 2010, 210, 240-250.	1.2	46
35	Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans. Alzheimer's and Dementia, 2010, 6, 239-246.	0.4	402
36	Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Review of Neurotherapeutics, 2010, 10, 985-1002.	1.4	58
37	Detection of amyloid plaques targeted by USPIO-AÎ²1â€“42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. NeuroImage, 2011, 55, 1600-1609.	2.1	126
38	Amyloid Clearance as a Treatment Target Against Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 61-73.	1.2	67

#	Article	IF	Citations
39	Solanezumab for Alzheimer's disease. Expert Opinion on Biological Therapy, 2011, 11, 787-798.	1.4	39
40	The Role of Tau in Alzheimer's Disease and Related Disorders. CNS Neuroscience and Therapeutics, 2011, 17, 514-524.	1.9	195
41	Current perspectives on pharmacotherapy of Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2011, 12, 335-350.	0.9	62
42	Report of the task force on designing clinical trials in early (predementia) AD. Neurology, 2011, 76, 280-286.	1.5	157
45	A Common Pathogenic Mechanism Linking Type-2 Diabetes and Alzheimer's Disease: Evidence from		

#	Article	IF	Citations
59	Cholinesterase inhibitors: a patent review (2007 â€“ 2011). Expert Opinion on Therapeutic Patents, 2012, 22, 853-869.	2.4	27
60	Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form. Neurobiology of Aging, 2012, 33, 1320-1328.	1.5	32
61	Experimental Inhibition of Peptide Fibrillogenesis by Synthetic Peptides, Carbohydrates and Drugs. Sub-Cellular Biochemistry, 2012, 65, 271-294.	1.0	0
62	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine. Bioorganic and Medicinal Chemistry, 2012, 20, 6669-6679.	1.4	66
63	Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease. PLoS ONE, 2012, 7, e32616.	1.1	329
64	Augmentation of catecholamine release elicited by an Eugenia punicifolia extract in chromaffin cells. Revista Brasileira De Farmacognosia, 2012, 22, 1-12.	0.6	4
65	Ligand-Based Design, Synthesis, and Biological Evaluation of 2-Aminopyrimidines, a Novel Series of Receptor for Advanced Glycation End Products (RAGE) Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 9120-9135.	2.9	52
66	An Aqueous Orally Active Vaccine Targeted Against a RAGE/AB Complex as a Novel Therapeutic for Alzheimerâ€™s Disease. NeuroMolecular Medicine, 2012, 14, 119-130.	1.8	18
67	Amyloid-Î² imaging with PET in Alzheimerâ€™s disease: is it feasible with current radiotracers and technologies?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 202-208.	3.3	40
68	The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimer's Research and Therapy, 2013, 5, 25.	3.0	71
69	Drug Discovery by Targeting Proteinâ€“Protein Interactions. , 2013, , 1-29.		1
70	Vascular disease and dementias: Paradigm shifts to drive research in new directions. Alzheimer's and Dementia, 2013, 9, 76-92.	0.4	117
71	Abnormal thiamine-dependent processes in Alzheimer's Disease. Lessons from diabetes. Molecular and Cellular Neurosciences, 2013, 55, 17-25.	1.0	69
72	Modulation of the cannabinoid receptors by hemopressin peptides. Life Sciences, 2013, 92, 520-524.	2.0	24
73	A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50â€ƒmg oral dose of the Î³â€secretase inhibitor avagacestat. British Journal of Clinical Pharmacology, 2013, 75, 136-145.	1.1	13
74	Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial. Journal of Neuroscience, 2013, 33, 4923-4934.	1.7	100
75	Frontal Network Syndrome Testing. American Journal of Alzheimer's Disease and Other Dementias, 2013, 28, 477-484.	0.9	8
76	Molecular Chaperones as Potential Therapeutic Targets for Neurological Disorders. RSC Drug Discovery Series, 2013, , 392-413.	0.2	1

#	Article	IF	Citations
77	AAD-2004 Attenuates Progressive Neuronal Loss in the Brain of Tg-betaCTF99/B6 Mouse Model of Alzheimer Disease. Experimental Neurobiology, 2013, 22, 31-37.	0.7	8
78	Carnosine's Effect on Amyloid Fibril Formation and Induced Cytotoxicity of Lysozyme. PLoS ONE, 2013, 8, e81982.	1.1	45
79	Fumanjian, a Classic Chinese Herbal Formula, Can Ameliorate the Impairment of Spatial Learning and Memory through Apoptotic Signaling Pathway in the Hippocampus of Rats withAÎ²_{1â€“40}-Induced Alzheimerâ€™s Disease. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-9.	0.5	11
80	Benefits of investment into modern medicines in Centralâ€“Eastern European countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 71-79.	0.7	11
81	Bringing rigour to translational medicine. Nature Reviews Neurology, 2014, 10, 37-43.	4.9	107
82	Social Workersâ€™ and Nursesâ€™ Illness Representations About Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2014, 28, 73-78.	0.6	15
83	Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures. European Journal of Pharmacology, 2014, 739, 83-95.	1.7	72
84	Epigallocatechin-3-gallate (EGCG)-Stabilized Selenium Nanoparticles Coated with Tet-1 Peptide To Reduce Amyloid-Î² Aggregation and Cytotoxicity. ACS Applied Materials & Interfaces, 2014, 6, 8475-8487.	4.0	156
85	Development of a dual nanocarrier system as a potential stratagem against amyloid-induced toxicity. Expert Opinion on Drug Delivery, 2014, 11, 1131-1147.	2.4	9
86	Synthesis and functional survey of new Tacrine analogs modified with nitroxides or their precursors. European Journal of Medicinal Chemistry, 2014, 77, 343-350.	2.6	9
87	Camptothecin and its Analogs Reduce Amyloid-Î² Production and Amyloid-Î²42-Induced IL-1Î² Production. Journal of Alzheimer's Disease, 2014, 43, 465-477.	1.2	11
88	Latrepirdine for Alzheimer's disease. The Cochrane Library, 2015, 2015, CD009524.	1.5	18
89	Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 50, 335-352.	1.2	42
90	How fisetin reduces the impact of age and disease on CNS function. Frontiers in Bioscience - Scholar, 2015, 7, 58-82.	0.8	85
91	The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced AmyloidÎ²Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. Journal of Immunology Research, 2015, 2015, 1-9.	0.9	5
92	Comparison of active contour and fast marching methods of hippocampus segmentation. , 2015, , .		1
93	<scp>A</scp>lzheimer's disease and chronic periodontitis: Is there an association?. Geriatrics and Gerontology International, 2015, 15, 391-404.	0.7	86
94	Simple approach to the synthesis of novel tricyclic BACE1 inhibitor warhead through Î²-lactam opening. Tetrahedron Letters, 2015, 56, 4028-4030.	0.7	9

#	Article	IF	Citations
95	Targeting disordered proteins with small molecules using entropy. Trends in Biochemical Sciences, 2015, 40, 491-496.	3.7	87
96	Chaperonotherapy for Alzheimerâ€™s Disease: Focusing on HSP60. Heat Shock Proteins, 2015, , 51-76.	0.2	5
97	Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. Journal of Immunological Methods, 2015, 424, 64-79.	0.6	15
98	Early Signs of Pathological Cognitive Aging in Mice Lacking High-Affinity Nicotinic Receptors. Frontiers in Aging Neuroscience, 2016, 8, 91.	1.7	11
99	Design of Peptide Substrate for Sensitively and Specifically Detecting Two AÎ²-Degrading Enzymes: Neprilysin and Angiotensin-Converting Enzyme. PLoS ONE, 2016, 11, e0153360.	1.1	8
100	Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2016, 92, 224-234.	1.9	183
101	Grapes and the Brain. , 2016, , 139-161.		0
102	Synthesis and biological evaluation of 8-hydroxy-2,7-naphthyridin-2-ium salts as novel inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). MedChemComm, 2017, 8, 465-470.	3.5	3
103	Molecular Pathogenesis of Alzheimer's Disease: An Update. Annals of Neurosciences, 2017, 24, 46-54.	0.9	289
104	Research advances in the treatment of Alzheimer's disease with polysaccharides from traditional Chinese medicine. Chinese Journal of Natural Medicines, 2017, 15, 641-652.	0.7	13
105	Patents Survey: Treatment of Alzheimerâ€™s Disease Through Nanotechnology-Based Drug Delivery System. , 2017, , 335-359.		1
106	Molecular Anti-inflammatory Mechanisms of Retinoids and Carotenoids in Alzheimerâ€™s Disease: a Review of Current Evidence. Journal of Molecular Neuroscience, 2017, 61, 289-304.	1.1	83
107	Molecular and Therapeutic Targets of Genistein in Alzheimerâ€™s Disease. Molecular Neurobiology, 2017, 54, 7028-7041.	1.9	61
108	Periodontitis as a Modifiable Risk Factor for Dementia: A Nationwide Populationâ€Based Cohort Study. Journal of the American Geriatrics Society, 2017, 65, 301-305.	1.3	77
109	Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors. Computational Biology and Chemistry, 2018, 74, 304-326.	1.1	68
110	Multi-Faceted Role of Melatonin in Neuroprotection and Amelioration of Tau Aggregates in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1481-1493.	1.2	34
111	The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials. Molecules, 2018, 23, 3283.	1.7	193
112	Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?. Neurotherapeutics, 2018, 15, 1032-1035.	2.1	8

#	Article	IF	Citations
113	A novel cognitive disease progression model for clinical trials in autosomalâ€dominant Alzheimer's disease. Statistics in Medicine, 2018, 37, 3047-3055.	0.8	31
114	Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of Controlled Release, 2018, 281, 139-177.	4.8	377
115	Nootropic medicinal plants: Therapeutic alternatives for Alzheimerâ€™s disease. Journal of Herbal Medicine, 2019, 17-18, 100291.	1.0	23
116	Advancements in nanotherapeutics for Alzheimerâ€™s disease: current perspectives. Journal of Pharmacy and Pharmacology, 2019, 71, 1370-1383.	1.2	108
117	Effects of the drug combination memantine and melatonin on impaired memory and brain neuronal deficits in an amyloid-predominant mouse model of Alzheimer's disease. Journal of Pharmacy and Pharmacology, 2019, 71, 1695-1705.	1.2	24
118	The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases. International Journal of Molecular Sciences, 2019, 20, 3056.	1.8	142
119	Identification of two novel peptides with antioxidant activity and their potential in inhibiting amyloid-Î² aggregation in vitro. Food and Function, 2019, 10, 1191-1202.	2.1	8
120	Vitamin A and Retinoic Acid in Cognition and Cognitive Disease. Annual Review of Nutrition, 2020, 40, 247-272.	4.3	70
121	The Potential Mechanisms of the Neuroprotective Actions of Oil Palm Phenolics: Implications for Neurodegenerative Diseases. Molecules, 2020, 25, 5159.	1.7	7
122	An Overview of Crucial Dietary Substances and Their Modes of Action for Prevention of Neurodegenerative Diseases. Cells, 2020, 9, 576.	1.8	20
123	Preventing and Treating Neurological Disorders with the Flavonol Fisetin. Brain Plasticity, 2021, 6, 155-166.	1.9	41
124	CART mitigates oxidative stress and DNA damage in memory deficits of APP/PS1 mice via upregulating Î²â€amyloid metabolismâ€associated enzymes. Molecular Medicine Reports, 2021, 23, .	1.1	14
125	The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimerâ€™s Disease. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	20
126	The Design of Electronic Tagging and Tracking Solutions to Improve the Safety and Person-Centered Care for People with Dementia. Lecture Notes in Computer Science, 2020, , 138-148.	1.0	1
127	Functional Neural Correlates of Attentional Deficits in Amnestic Mild Cognitive Impairment. PLoS ONE, 2013, 8, e54035.	1.1	48
128	Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy. PLoS ONE, 2013, 8, e72301.	1.1	201
129	The Signal Transducer and Activator of Transcription 1 (STAT1) Inhibits Mitochondrial Biogenesis in Liver and Fatty Acid Oxidation in Adipocytes. PLoS ONE, 2015, 10, e0144444.	1.1	39
130	Therapeutic Approaches to Alzheimerâ€™s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection. Current Pharmaceutical Design, 2019, 25, 2555-2568.	0.9	25

#	Article	IF	Citations
131	Protein Homeostasis as a Therapeutic Target for Diseases of Protein Conformation. Current Topics in Medicinal Chemistry, 2013, 12, 2623-2640.	1.0	81
132	Emerging Promise of Immunotherapy for Alzheimerâ€™s Disease: A New Hope for the Development of Alzheimerâ€™s Vaccine. Current Topics in Medicinal Chemistry, 2020, 20, 1214-1234.	1.0	22
133	Effects of Mulberry on The Central Nervous System: A Literature Review. Current Neuropharmacology, 2020, 19, 193-219.	1.4	9
134	A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes. CNS and Neurological Disorders - Drug Targets, 2014, 13, 478-486.	0.8	15
135	A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (AÎ²) production. Bioinformation, 2010, 5, 122-127.	0.2	6
136	Protective Effects of Citicoline and Benfotiamine Each Alone and in Combination on Streptozotocin-induced Memory Impairment in Mice. Clinical Psychopharmacology and Neuroscience, 2020, 18, 81-92.	0.9	10
138	Diagnosis of Dementia Using Nuclear Medicine Imaging Modalities. , 0, , .		0
139	- Developing Drugs from Sugars: Current State of Glycosaminoglycan-Derived Therapeutics. , 2012, , 274-335.		0
140	Developing Drugs from Sugars. , 2012, , 259-296.		0
142	Glucose and Ketone Metabolism in the Aging Brain. , 2016, , .		1
143	Tapping into the Potential of Cinnamon as a Therapeutic Agent in Neurological Disorders and Metabolic Syndrome. , 2020, , 273-305.		0
144	Hsp70 ATPase Modulators as Therapeutics for Alzheimer's and other Neurodegenerative Diseases. Molecular and Cellular Pharmacology, 2010, 2, 43-46.	1.7	40
149	Using Plants as a Source of Potential Therapeutics for the Treatment of Alzheimer's Disease. Yale Journal of Biology and Medicine, 2020, 93, 365-373.	0.2	2
150	The Role of ERK1/2 Pathway in the Pathophysiology of Alzheimerâ€™s Disease: An Overview and Update on New Developments. Cellular and Molecular Neurobiology, 2023, 43, 177-191.	1.7	22
151	Role of Clathrin and Dynamin in Clathrin Mediated Endocytosis/Synaptic Vesicle Recycling and Implications in Neurological Diseases. Frontiers in Cellular Neuroscience, 2021, 15, 754110.	1.8	16
153	Computational decision-support tools for urban design to improve resilience against COVID-19 and other infectious diseases: A systematic review. Progress in Planning, 2023, 168, 100657.	2.3	7
154	Endocytosis in Î²-amyloid biology and Alzheimerâ€™s disease. , 2022, , 111-131.		0
155	Brain targeting drug delivery systems for the management of brain disorders. , 2022, , 289-345.		0

#	Article	IF	Citations
156	Early interventions for post-traumatic stress following musculoskeletal trauma: protocol for a systematic review and meta-analysis. BMJ Open, 2022, 12, e065590.	0.8	0
157	Sintomas de ansiedade em adultos jovens: a atuaÃ§Ã£o do profissional de psicologia na atenÃ§Ã£o bÃ¡sica. Revista Debates Em Psiquiatria, 0, 12, 1-22.	0.3	0
158	The Role of Caspases in Alzheimerâ€™s Disease: Pathophysiology Implications and Pharmacologic Modulation. Journal of Alzheimer's Disease, 2022, , 1-20.	1.2	3
159	Neuroprotective Potential and Underlying Pharmacological Mechanism of Carvacrol for Alzheimerâ€™s and Parkinsonâ€™s Diseases. Current Neuropharmacology, 2023, 21, 1421-1432.	1.4	4
160	Lifestyle modifications and nutrition in Alzheimer's disease. , 2023, , 13-39.		0